Skip to main content

Table 3 Hazard ratios (HRs) and 95 % confidence intervals (CIs) for fractures and potential risk factors in the time-dependent model

From: Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study

Variable

Crude HR (95 % CI)

p-value

Adjusted HR (95 % CI)

p-value

Age, years

1.10

(1.10-1.11)

<0.0001

1.09

(1.08-1.10)

<0.0001

Monthly income, NTD

      

<= 15000

4.85

(3.98-5.91)

<0.0001

1.34

(1.08-1.66)

0.009

15001-20000

2.25

(1.86-2.71)

<0.0001

1.51

(1.25-1.82)

<0.0001

>20000

1.00

Ref.

 

1.00

Ref.

 

Comorbidity (yes vs. no)

      

Hypertension

4.48

(3.94-5.09)

<0.0001

1.27

(1.09-1.48)

0.002

Hyperlipidemia

2.19

(1.92-2.50)

<0.0001

0.83

(0.72-0.96)

0.01

Diabetes

3.65

(3.18-4.19)

<0.0001

1.59

(1.37-1.85)

<0.0001

PAD

2.74

(2.00-3.74)

<0.0001

0.99

(0.72-1.36)

0.96

Stroke

5.40

(4.27-6.83)

<0.0001

1.38

(1.08-1.76)

0.01

Osteoporosis

3.11

(2.70-3.58)

<0.0001

1.38

(1.19-1.59)

<0.0001

Aromatase inhibitor use before the end point

1.18

(1.00-1.40)

0.049

0.80

(0.68-0.95)

0.01

  1. Manually adjusted for tamoxifen use, age, monthly income, comorbidity and aromatase inhibitor use before the end point
  2. PAD, peripheral artery disease